Cargando…
The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice
Patients with psoriatic arthritis (PsA) often develop joint symptoms years after their initial diagnosis of psoriasis disease; therefore, dermatologists should test for and detect PsA early. In this study, we focused on patients with psoriasis with both nail and joint disease being treated with tumo...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620057/ https://www.ncbi.nlm.nih.gov/pubmed/34834435 http://dx.doi.org/10.3390/jpm11111083 |
_version_ | 1784605133430063104 |
---|---|
author | Kokolakis, Georgios Sabat, Robert Fischer, Imma Gomis-Kleindienst, Susana Fritz, Björn Burmester, Gerd-Rüdiger Ghoreschi, Kamran Ohrndorf, Sarah |
author_facet | Kokolakis, Georgios Sabat, Robert Fischer, Imma Gomis-Kleindienst, Susana Fritz, Björn Burmester, Gerd-Rüdiger Ghoreschi, Kamran Ohrndorf, Sarah |
author_sort | Kokolakis, Georgios |
collection | PubMed |
description | Patients with psoriatic arthritis (PsA) often develop joint symptoms years after their initial diagnosis of psoriasis disease; therefore, dermatologists should test for and detect PsA early. In this study, we focused on patients with psoriasis with both nail and joint disease being treated with tumor necrosis factor-α inhibitors by dermatologists. We performed a noninterventional, prospective, multicenter, and open-label study to evaluate the effectiveness of adalimumab, etanercept, or infliximab over 24 months of continuous therapy in patients with moderate to severe plaque-type psoriasis (Pso) and PsA. Disease assessments with the Psoriasis Area and Severity Index, Nail Psoriasis Severity Index (NAPSI), joint assessment, Dermatology Life Quality Index (DLQI), and Health Assessment Questionnaire (HAQ) instruments were performed every 3 months for the first year and twice annually thereafter. The cohort included 100 patients with Pso, nail psoriasis, and PsA. A significant reduction of NAPSI was observed 3 months after therapy initiation compared with the baseline (mean ± SD, 22.9 ± 17.8 vs. 33.8 ± 21.4; p < 0.001). Similarly, the mean ± SD number of both tender and swollen joints decreased significantly within the first 3 months of treatment, from 10.8 ± 11.5 to 6.4 ± 10.3 (p < 0.001) and from 6.4 ± 9.5 to 3.1 ± 7.2 (p < 0.001), respectively. Additionally, the distal interphalangeal joint involvement improved throughout the observation time, and DLQI and HAQ scores decreased. Improvements in control of skin, nail, and joint symptoms were seen, as well as in patients’ quality of life and functionality. Dermatologists have an important role not only in PsA diagnosis but also in PsA long-term care. |
format | Online Article Text |
id | pubmed-8620057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86200572021-11-27 The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice Kokolakis, Georgios Sabat, Robert Fischer, Imma Gomis-Kleindienst, Susana Fritz, Björn Burmester, Gerd-Rüdiger Ghoreschi, Kamran Ohrndorf, Sarah J Pers Med Article Patients with psoriatic arthritis (PsA) often develop joint symptoms years after their initial diagnosis of psoriasis disease; therefore, dermatologists should test for and detect PsA early. In this study, we focused on patients with psoriasis with both nail and joint disease being treated with tumor necrosis factor-α inhibitors by dermatologists. We performed a noninterventional, prospective, multicenter, and open-label study to evaluate the effectiveness of adalimumab, etanercept, or infliximab over 24 months of continuous therapy in patients with moderate to severe plaque-type psoriasis (Pso) and PsA. Disease assessments with the Psoriasis Area and Severity Index, Nail Psoriasis Severity Index (NAPSI), joint assessment, Dermatology Life Quality Index (DLQI), and Health Assessment Questionnaire (HAQ) instruments were performed every 3 months for the first year and twice annually thereafter. The cohort included 100 patients with Pso, nail psoriasis, and PsA. A significant reduction of NAPSI was observed 3 months after therapy initiation compared with the baseline (mean ± SD, 22.9 ± 17.8 vs. 33.8 ± 21.4; p < 0.001). Similarly, the mean ± SD number of both tender and swollen joints decreased significantly within the first 3 months of treatment, from 10.8 ± 11.5 to 6.4 ± 10.3 (p < 0.001) and from 6.4 ± 9.5 to 3.1 ± 7.2 (p < 0.001), respectively. Additionally, the distal interphalangeal joint involvement improved throughout the observation time, and DLQI and HAQ scores decreased. Improvements in control of skin, nail, and joint symptoms were seen, as well as in patients’ quality of life and functionality. Dermatologists have an important role not only in PsA diagnosis but also in PsA long-term care. MDPI 2021-10-25 /pmc/articles/PMC8620057/ /pubmed/34834435 http://dx.doi.org/10.3390/jpm11111083 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kokolakis, Georgios Sabat, Robert Fischer, Imma Gomis-Kleindienst, Susana Fritz, Björn Burmester, Gerd-Rüdiger Ghoreschi, Kamran Ohrndorf, Sarah The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice |
title | The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice |
title_full | The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice |
title_fullStr | The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice |
title_full_unstemmed | The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice |
title_short | The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice |
title_sort | effect of tnf-α inhibitors on nail psoriasis and psoriatic arthritis—real-world data from dermatology practice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620057/ https://www.ncbi.nlm.nih.gov/pubmed/34834435 http://dx.doi.org/10.3390/jpm11111083 |
work_keys_str_mv | AT kokolakisgeorgios theeffectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT sabatrobert theeffectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT fischerimma theeffectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT gomiskleindienstsusana theeffectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT fritzbjorn theeffectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT burmestergerdrudiger theeffectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT ghoreschikamran theeffectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT ohrndorfsarah theeffectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT kokolakisgeorgios effectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT sabatrobert effectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT fischerimma effectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT gomiskleindienstsusana effectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT fritzbjorn effectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT burmestergerdrudiger effectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT ghoreschikamran effectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice AT ohrndorfsarah effectoftnfainhibitorsonnailpsoriasisandpsoriaticarthritisrealworlddatafromdermatologypractice |